You and KC make valid points that generally reflect my opinion. Items 1 and 2 cannot be overstated. Given the company's never-ending need to fund trials, it's hard to argue with Item 3. Although how do you keep good people, if you don't pay them?

However, Item 4 must also include navigating and negotiating with the FDA. Dr. J has proven his ability to do that. Adding to your post that Cytodyn needs a "proven business CEO' as well as a "research MD", I would suggest the company also needs a skilled negotiator. As the song says, "Two out of three ain't bad".

Let's not forget that he also took it upon himself to contact the survivors who participated in the previous trials in order to glean their information. His findings were annotated so that they became more than anecdotes. Perhaps Hoffman is supposed to fill that business role and is yet to succeed. Dr. J can be held accountable for that failure, if it turns out to be a failure.